Single-agent vinorelbine as third-line chemotherapy for refractory non-small cell lung cancer

Turkish Journal of Cancer

Volumn 36, Issue 3, 2006, Pages 133-137

  Kanat, Özkan ^a   Ölmez, Fatih ^a   Kurt, Ender ^a   Yildiz, Abdülmecit ^a   Evrensel, Türkkan ^a   Kanat, Elvan ^a   Manavoǧlu, Osman ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Refractory non small cell lung cancer; Salvage regimen; Third line chemotherapy; Vinorelbine

Indexed keywords

GRANISETRON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NAVELBINE; PLATINUM; TAXANE DERIVATIVE; TROPISETRON;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 34249716310     PISSN: 10193103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multi-center randomized trial. J Clin Oncol 1998;6:633-41.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 1993;342:19-21.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
5. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
7. Ozdogan M, Samur M, Bozcuk H, et al. Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study. Turk J Cancer 2004;34:19-23.
8. Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 1994;11(Suppl 1):130.
9. Rinaldi M, Della GM, Vanturo I, et al. Vinorelbine as a single agent in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1994;13:p360.
10. Pronzato P, Landucci M, Vaira F, et al. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 1994;14:1413-6.
11. Chen YM, Tsai CM, Perng RP. Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed. J Chin Med Assoc 2005; 68:163-6.
12. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005;23:3235-42.
13. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.